A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Abstract Background Chromosome translocations involving mixed lineage leukemia 1 (MLL1) cause acute leukemia in most infants and 5–10% children/adults with dismal clinical outcomes. Most frequent MLL1-fusion partners AF4/AFF4, AF9/ENL and ELL, together with CDK9/cyclin-T1, constitute super elongatio...

Full description

Bibliographic Details
Main Authors:	Xin Li, Yuan Yao, Fangrui Wu, Yongcheng Song
Format:	Article
Language:	English
Published:	BMC 2022-04-01
Series:	Journal of Hematology & Oncology
Subjects:	PROTAC ENL MLL1-rearranged leukemia ENL mutation Cancer therapeutics
Online Access:	https://doi.org/10.1186/s13045-022-01258-8

Similar Items

HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis
by: Satoshi Takahashi, et al.
Published: (2021-08-01)

Immunoglobulin deposits in Erythema Nodosum Leprosum (ENL) JOSEPHINE ANTHON
by: JOSEPHINE ANTHONY, et al.
Published: (1978-06-01)

Kelainan Sistemik dan Laboratorik pada Pasien Kusta dengan Reaksi Tipe 2/ ENL di Divisi Kusta Unit Rawat Jalan dan Instalasi Rawat Inap SMF Kesehatan Kulit dan Kelamin RSUD Dr. Soetomo Surabaya Periode 2011-2013
by: Febrina Dewi Pratiwi, et al.
Published: (2018-05-01)

Beneficial Effect of Minocycline as Additional Treatment to Prednisone for Pustular Erythema Nodosum Leprosum
by: Gunawan H, et al.
Published: (2022-05-01)

Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports
by: Pugazhenthan Thangaraju, et al.
Published: (2020-09-01)

Discovery, Structure–Activity Relationship and In Vitro Anticancer Activity of Small-Molecule Inhibitors of the Protein–Protein Interactions between AF9/ENL and AF4 or DOT1L
by: Xin Li, et al.
Published: (2023-11-01)

Limited permissibility of ENL-R and Mv-1-Lu mink cell lines to SARS-CoV-2
by: Marion Le Bideau, et al.
Published: (2022-10-01)

Higher Level Zinc Serum in Multibacillary Leprosy With Erythema Nodosum Leprosum compared to Patients Without Reaction
by: Kinanti Prabawaningrum, et al.
Published: (2016-09-01)

Borderline Lepromatous Leprosy with Severe Erythema Nodosum Leprosum: A Case Report
by: Nevristia Pratama, et al.
Published: (2022-11-01)

Spatially adaptive polarimetric image despeckling using bandelet transform
by: Roy Thankachan, et al.
Published: (2020-06-01)

Esquemas tributarios de las entidades No lucrativas en México
by: Daniel Eduardo Paz Pérez
Published: (2020-06-01)

Forgive sins: rise of thalidomide
by: Yugandar Inakanti, et al.
Published: (2014-04-01)

Editorial: The Role of Biomarkers in the Immunopathology and Diagnosis of Immune Exacerbations in Leprosy—New Frontiers to Manage This Neglected Disease
by: Paulo R. Z. Antas, et al.
Published: (2022-03-01)

Host-Related Laboratory Parameters for Leprosy Reactions
by: Yuqian Luo, et al.
Published: (2021-10-01)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
by: Zizhen Feng, et al.
Published: (2016-03-01)

Evaluating the efficacy of apremilast combined with low-dose steroids versus combination of apremilast with low-dose steroids and low-dose aspirin for selected cases in the management of erythema nodusum leprosum: A pilot study
by: Nitin Krishna Patil, et al.
Published: (2023-01-01)

Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions
by: Anthony K. N. Chan, et al.
Published: (2019-05-01)

Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum
by: Gustavo U. Machado, et al.
Published: (2023-10-01)

Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia
by: Farinoosh Dadrass, et al.
Published: (2022-08-01)

Extranodal Non-Hodgkin Lymphomas: The Impact of Different Variables on the Disease
by: Veenita Yogi, et al.
Published: (2019-10-01)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01)

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
by: Xuyang Zhao, et al.
Published: (2023-04-01)

Congenital B-lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution to mixed phenotype acute leukemia
by: Elizabeth Moschiano, et al.
Published: (2016-01-01)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
by: Alexia Tsakaneli, et al.
Published: (2021-09-01)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
by: Yonghan He, et al.
Published: (2020-07-01)

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
by: Xinyi Li, et al.
Published: (2022-04-01)

Clinical and biological features of acute myeloid leukemia with MLL gene rearrangements in children and results of therapy according to protocols AML-MM-2000/2006 in the Republic of Belarus
by: Yu. A. Barovskaya, et al.
Published: (2019-01-01)

SETD2 in MLL-rearranged leukemia – a complex case
by: Anna Skucha, et al.
Published: (2018-07-01)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
by: Li Liu, et al.
Published: (2022-03-01)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
by: Rui Li, et al.
Published: (2022-12-01)

Design, Synthesis, and Antitumor Activity Evaluation of Proteolysis-Targeting Chimeras as Degraders of Extracellular Signal-Regulated Kinases 1/2
by: Pengming Pan, et al.
Published: (2023-11-01)

Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
by: Xin Li, et al.
Published: (2021-04-01)

Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras
by: Tianzhi Wen, et al.
Published: (2023-05-01)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
by: Mingxing Hu, et al.
Published: (2020-10-01)

Detection of New Translocation in Infant Twins with Concordant ALL and Discordant Outcome
by: Golamreza Bahoush, et al.
Published: (2020-12-01)

Computer aided drug design in the development of proteolysis targeting chimeras
by: Tin M. Tunjic, et al.
Published: (2023-01-01)

Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
by: Sudhakar Manda, et al.
Published: (2020-04-01)

Multi-Temporal Speckle Filtering of Polarimetric P-Band SAR Data over Dense Tropical Forests: Study Case in French Guiana for the BIOMASS Mission
by: Colette Gelas, et al.
Published: (2021-01-01)

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
by: Shenxin Zeng, et al.
Published: (2021-03-01)